XCNQ
ENBI
Market cap1mUSD
, Last price
CAD
Name
Entheon Biomedical Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.15%
Rev. gr., 5y
%
Revenues
250k
+31.97%
Net income
-300k
L-95.73%
CFO
-356k
L-1.19%
Earnings
Jul 02, 2025
Profile
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑11 | 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2020‑03 | 2019‑11 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||||
Revenues | 250 31.97% | 190 775.30% | |||||||||
Cost of revenue | 564 | 3,790 | |||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (314) | (3,600) | |||||||||
NOPBT Margin | |||||||||||
Operating Taxes | 4,970 | ||||||||||
Tax Rate | |||||||||||
NOPAT | (314) | (8,571) | |||||||||
Net income | (300) -95.73% | (7,032) -18.89% | |||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 22 | 155 | |||||||||
Net debt | (136) | (350) | (705) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (356) | (360) | (1,955) | ||||||||
CAPEX | |||||||||||
Cash from investing activities | 24 | 586 | |||||||||
Cash from financing activities | 148 | ||||||||||
FCF | (26) | (314) | (8,175) | ||||||||
| Balance | |||||||||||
Cash | 136 | 345 | 680 | ||||||||
Long term investments | 5 | 25 | |||||||||
Excess cash | 136 | 337 | 696 | ||||||||
Stockholders' equity | 145 | 316 | 615 | ||||||||
Invested Capital | 31 | ||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 5,909 | 5,909 | |||||||||
Price | 0.14 1,300.00% | 0.01 -66.67% | 0.03 -94.44% | ||||||||
Market cap | 59 -66.67% | 177 -93.95% | |||||||||
EV | (291) | (528) | |||||||||
EBITDA | (314) | (3,598) | |||||||||
EV/EBITDA | 0.93 | 0.15 | |||||||||
Interest | 1,489 | ||||||||||
Interest/NOPBT | |||||||||||